argenx (ARGX) Q4 2025 earnings summary

Executive summary

• Achieved $4.2 billion in full-year 2025 global product net sales, up 90% year-over-year, and $1.3 billion in Q4 sales, marking the first year of operating profitability with $1.1 billion in operating income.

• Treated 19,000 patients globally and launched a prefilled syringe for self-injection, driving strong adoption and making VYVGART the #1 prescribed biologic in MG.

• Positive Phase 3 ADAPT-OCULUS results in ocular and seronegative MG support broad label expansion in the U.S., with sBLA filing planned for ocular MG.

• Continued expansion into CIDP, autoimmune myositis, Sjögren's disease, MMN, and rheumatology, with a robust late-stage pipeline and next-generation FcRn assets advancing.

• Leadership transition announced, with a focus on operational discipline and Vision 2030 targeting 50,000 patients on treatment and 10 labeled indications by 2030.

Financial highlights

• Q4 2025 product net sales reached $1.3 billion; full-year net sales were $4.2 billion, up 90% year-over-year.

• U.S. Q4 product sales were $1.1 billion, up 68% from the prior year; Japan, RoW, and China also saw triple-digit percentage growth.

• Operating profit for Q4 was $367–368 million and $1.1 billion for the year, with full-year net profit of $1.29–1.3 billion.

• Cash and equivalents at year-end totaled $4.4 billion, up over $1 billion year-over-year.

• Combined R&D and SG&A expenses for the year were $2.7 billion, in line with guidance.

Outlook and guidance

• Operating expenses expected to grow at a similar rate in 2026, with most growth in R&D to support pipeline advancement.

• Revenue growth anticipated to outpace OpEx growth, supporting increasing operating margins and long-term profitability.

• Label expansions in seronegative and ocular MG expected to add 18,000 addressable patients in the U.S.; PDUFA action date for seronegative gMG set for May 10, 2026.

• Auto-injector launch planned for 2027, with continued innovation in delivery modalities.

• Four Phase 3 molecules and 10 clinical-stage molecules expected in pipeline by end of 2026.